> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Akorn Pays $7.9 Million to Resolve False Claims Suit
- URL: https://www.fdaweb.com/akorn-pays-7-9-million-to-resolve-false-claims-suit/
- Published: 2022-09-15T12:00:00.000Z
- Updated: 2026-09-14T17:59:32.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152749

The Justice Department says Akorn Operating Company, an Illinois pharmaceutical company, has agreed to pay $7.9 million to resolve a whistleblower’s allegations that it caused Medicare to pay false claims by delaying its request to FDA to switch drugs from prescription to over-the-counter. A department [statement](https://www.justice.gov/usao-ma/pr/pharmaceutical-company-akorn-operating-company-llc-agrees-pay-79-million-resolve?ref=fdaweb.com) says Akorn caused Medicare Part D to pay for three generic drugs that were no longer eligible for Medicare coverage. As part of the settlement, it says, Akorn admits that it continued to sell generic drugs under obsolete prescription-only labeling.

The whistleblower will receive about $946,000 from the settlement proceeds, the statement says.